4-methyl-umbelliferyl-N-acetyl-chitobiose

Identification

Generic Name
4-methyl-umbelliferyl-N-acetyl-chitobiose
DrugBank Accession Number
DB02759
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 582.5538
Monoisotopic: 582.206089184
Chemical Formula
C26H34N2O13
Synonyms
  • 4-methylumbelliferyl-N,N-diacetylchitobioside
  • 4-Mudacb

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ULysozyme CNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as coumarin glycosides. These are aromatic compounds containing a carbohydrate moiety glycosidically bound to a coumarin moiety.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Coumarin glycosides
Direct Parent
Coumarin glycosides
Alternative Parents
N-acyl-alpha-hexosamines / Disaccharides / O-glycosyl compounds / 1-benzopyrans / Pyranones and derivatives / Oxanes / Benzenoids / Acetamides / Heteroaromatic compounds / Secondary alcohols
show 10 more
Substituents
1-benzopyran / Acetal / Acetamide / Alcohol / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran / Carbonyl group / Carboxamide group / Carboxylic acid derivative
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
SYW68VG2T6
CAS number
53643-12-2
InChI Key
UPSFMJHZUCSEHU-JYGUBCOQSA-N
InChI
InChI=1S/C26H34N2O13/c1-10-6-18(33)38-15-7-13(4-5-14(10)15)37-25-20(28-12(3)32)23(36)24(17(9-30)40-25)41-26-19(27-11(2)31)22(35)21(34)16(8-29)39-26/h4-7,16-17,19-26,29-30,34-36H,8-9H2,1-3H3,(H,27,31)(H,28,32)/t16-,17-,19-,20-,21-,22-,23-,24-,25-,26+/m1/s1
IUPAC Name
N-[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4R,5R,6S)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-[(4-methyl-2-oxo-2H-chromen-7-yl)oxy]oxan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
SMILES
[H]N([C@H]1[C@H](O[C@@H]2[C@@H](CO)O[C@@H](OC3=CC4=C(C=C3)C(C)=CC(=O)O4)[C@H](N([H])C(C)=O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O)C(C)=O

References

General References
Not Available
PubChem Compound
171284
PubChem Substance
46507800
ChemSpider
149747
ZINC
ZINC000015288235
PDBe Ligand
GUM
PDB Entries
1bb7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.55 mg/mLALOGPS
logP-0.81ALOGPS
logP-2.8Chemaxon
logS-2ALOGPS
pKa (Strongest Acidic)11.75Chemaxon
pKa (Strongest Basic)-1.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count12Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area222.57 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity134.57 m3·mol-1Chemaxon
Polarizability57.83 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9068
Blood Brain Barrier-0.9838
Caco-2 permeable-0.842
P-glycoprotein substrateSubstrate0.5705
P-glycoprotein inhibitor INon-inhibitor0.7945
P-glycoprotein inhibitor IINon-inhibitor0.8362
Renal organic cation transporterNon-inhibitor0.9544
CYP450 2C9 substrateNon-substrate0.7342
CYP450 2D6 substrateNon-substrate0.8519
CYP450 3A4 substrateSubstrate0.5294
CYP450 1A2 substrateNon-inhibitor0.9199
CYP450 2C9 inhibitorNon-inhibitor0.8981
CYP450 2D6 inhibitorNon-inhibitor0.9323
CYP450 2C19 inhibitorNon-inhibitor0.9001
CYP450 3A4 inhibitorNon-inhibitor0.9104
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7708
Ames testNon AMES toxic0.6626
CarcinogenicityNon-carcinogens0.9281
BiodegradationNot ready biodegradable0.9461
Rat acute toxicity2.1607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9832
hERG inhibition (predictor II)Non-inhibitor0.6931
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0101190000-727b9f400e274644b6c1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fsc-0330090000-405540fd15088f24c06a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f8i-2644490000-fb19d980d5e755ecafb8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0112290000-52415f72e51c155ee953
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0il9-8945120000-d0851a4465311547b2f0
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-005c-5814290000-dcbd21e123a60814b73c
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-232.5627677
predicted
DarkChem Lite v0.1.0
[M-H]-220.0608
predicted
DeepCCS 1.0 (2019)
[M+H]+231.9672677
predicted
DarkChem Lite v0.1.0
[M+H]+222.11186
predicted
DeepCCS 1.0 (2019)
[M+Na]+232.5368677
predicted
DarkChem Lite v0.1.0
[M+Na]+228.55544
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Lysozyme activity
Specific Function
Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.
Gene Name
LYZ
Uniprot ID
P61626
Uniprot Name
Lysozyme C
Molecular Weight
16536.885 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52